Search - tctmd.com

Displaying 1 - 20 of 468

Sort: Relevancy | Date

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Daily News

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

Caitlin E. Cox

October 16, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care

Caitlin E. Cox

March 19, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

ACC/AHA Release New Comprehensive ACS Guidelines

Todd Neale

February 27, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

Advertisement

Risk Calculators Miss Many Patients Who Present With First MI

Two New Scores Help Hone 10-Year CV Death Risk in ASCVD Patients

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Evolocumab Wins for Primary Prevention in VESALIUS-CV

CVD Still the Leading Cause of Death and Disease Globally

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

FDA Approves Triple Therapy Polypill for High Blood Pressure

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

ACC/AHA Release New Comprehensive ACS Guidelines

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content